内静脉血栓溶解在中风和癌症的背景下
Alessandra Burini1,2, Maurizio Paciaroni3, Lucio D'Anna4,5
1Clinical Neurology, Department of Medicine (DMED), University of Udine, Udine, Italy. alessandra.burini96@gmail.com.
Journal of thrombosis and thrombolysis
|July 17, 2025
概括
静脉内血栓溶解 (IVT) 对于患有缺血性中风的癌症患者来说似乎是安全的,但个性化治疗至关重要. 仔细考虑禁忌和癌症特异性因素对于这个高风险组的最佳结果至关重要.
科学领域:
- 神经学 神经学
- 在瘤学瘤学.
- 心血管医学 心血管医学
背景情况:
- 癌症患者面临缺血性和出血性中风的风险增加.
- 癌症患者的缺血性中风通常表现出独特的特征,如未知原因,多种病变和与癌症相关的凝血病,使治疗复杂化.
- 由于这些复杂性,癌症患者中风的管理策略需要仔细考虑.
研究的目的:
- 审查和评估静脉血栓溶解 (IVT) 治疗癌症患者急性缺血性中风的安全性和有效性.
- 在这个特定的患者群体中分析与血栓抑制药物治疗相关的风险和益处.
- 综合当前关于癌症患者中风治疗的文献和指南.
主要方法:
- 对PubMed进行了全面的文献审查,包括国际指南,元分析,队列研究和案例系列.
- 搜索涵盖了所有时间段,以收集有关癌症患者急性缺血性中风IVT的广泛数据.
- 审查的重点是评估血栓溶解干预措施的安全性和治疗效果.
主要成果:
- 目前的证据表明,IVT对于患有缺血性中风的癌症患者通常是安全有效的,尽管缺乏随机试验.
- 治疗IVT的决策必须是个性化的,考虑到患者特定的禁忌和瘤特征.
- 关于消化道或轴内瘤等禁忌的指导方针之间存在差异.
结论:
- 建议在癌症患者的缺血性中风中进行个性化IVT治疗,平衡风险和益处.
- 密切关注凝血状况,最近的手术史和同时服用的药物至关重要.
- 需要进一步的多中心,前性研究,以根据瘤部位,组织学和分子特征来完善风险分层.
相关概念视频
01:29Venous Thrombosis III: Interprofessional Care
25
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
25
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
46
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
46
01:30Venous Thrombosis IV: Nursing Management
25
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
25
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:27Pulmonary Embolism III: Nursing Management
42
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
42
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K